Work

PULSE: A randomized phase II open label study of panitumumab rechallenge versus standard therapy after progression on anti-EGFR therapy in patients with RAS wild-type metastatic colorectal cancer (mCRC).

Year: 2021

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2021.39.3_suppl.tps143

Authors: John H. Strickler, Fang-Shu Ou, Tanios S. Bekaii-Saab, Christine Megerdichian Parseghian, Andrea Cercek, Kimmie Ng, Federico Augusto Sanchez, Sarah Bruggeman, Joseph J. Larson, Gene Grant Finley, Joleen M. Hubbard, Christina Wu, Heinz-Josef Lenz, Scott Kopetz, Ryan Bruce Corcoran

Institutions: Duke Medical Center, Mayo Clinic, Mayo Clinic Hospital, The University of Texas MD Anderson Cancer Center, Memorial Sloan Kettering Cancer Center, Dana-Farber Cancer Institute, Aurora Health Care, Emory University, USC Norris Comprehensive Cancer Center, Massachusetts General Hospital

Language: English

Topic: Colorectal Cancer Treatments and Studies

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

Funder: Amgen

OpenAlex ID: W3122055085

Cites:

Cited by: 7

Related to: 10